%0 Journal Article
%A Fraunberger, Peter
%A Gröne, Elisabeth
%A Gröne, Hermann-Josef
%A Drexel, Heinz
%A Walli, Autar K
%T Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs.
%J Journal of Inflammation
%V 14
%N 1
%@ 1476-9255
%C London
%I BioMed Central
%M DKFZ-2017-00953
%P 3
%D 2017
%X Statins (HMG CoA reductase inhibitors), in addition to reducing circulating cholesterol and incidence of coronary heart disease, also have pleiotropic, anti-inflammatory effects. Patients with chronic liver diseases, non-alcoholic fatty liver disease (NAFLD) or hepatitis C are often excluded from statin therapy because of adverse effects in a small cohort of patients despite increased cardiovascular risk cholesterol. Ezetimibe, which inhibits cholesterol absorption by inhibition of Niemann-Pick C1 like 1 (NPC1L1) protein in the brush border of intestinal cells, has been suggested as a new therapeutic option in these patients.Effects of ezetimibe on lipoprotein metabolism, hepatic and intestinal lipid content in guinea pigs, an animal model with a lipoprotein profile and pattern similar to humans were investigated. In order to investigate a possible effect of ezetimibe on cholesterol induced inflammation NF-kappaB activation as an indicator for inflammatory processes in liver and gut tissue was measured.Lipid enriched diet led to accumulation of lipids in hepatic tissue which caused strong hepatic NF-kappaB activation. Ezetimibe reduced lipid diet induced increase of circulating cholesterol by about 77
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:28167864
%2 pmc:PMC5288872
%R 10.1186/s12950-017-0150-y
%U https://inrepo02.dkfz.de/record/120524